AMGN vs. VRTX, REGN, GILD, MRNA, SGEN, BIIB, ALNY, BMRN, NBIX, and INCY
Should you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD), Moderna (MRNA), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), and Incyte (INCY). These companies are all part of the "medical" sector.
Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.
Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.
Vertex Pharmaceuticals received 30 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 75.63% of users gave Vertex Pharmaceuticals an outperform vote while only 72.41% of users gave Amgen an outperform vote.
Amgen has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.
Amgen presently has a consensus price target of $305.65, suggesting a potential upside of 0.21%. Vertex Pharmaceuticals has a consensus price target of $438.62, suggesting a potential downside of 9.20%. Given Amgen's stronger consensus rating and higher possible upside, equities analysts clearly believe Amgen is more favorable than Vertex Pharmaceuticals.
Vertex Pharmaceuticals has a net margin of 39.46% compared to Amgen's net margin of 12.74%. Amgen's return on equity of 156.21% beat Vertex Pharmaceuticals' return on equity.
In the previous week, Vertex Pharmaceuticals had 9 more articles in the media than Amgen. MarketBeat recorded 30 mentions for Vertex Pharmaceuticals and 21 mentions for Amgen. Amgen's average media sentiment score of 0.94 beat Vertex Pharmaceuticals' score of 0.85 indicating that Amgen is being referred to more favorably in the media.
76.5% of Amgen shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 0.7% of Amgen shares are held by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Amgen and Vertex Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Amgen News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
